Ventyx Biosciences, Inc.: Ventyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque Psoriasis
ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address
United States Mecklenburg Vorpommern William Sandborn Ventyx Biosciences Stefan Klotter Ventyx Biosciences Inc
Source: finanznachrichten.de